EBITDA for DexCom (DXCM)
According to DexCom's latest reported financial statements, the company's current EBITDA (TTM) is $1.34B USD. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
DXCM
Currently viewingEBITDASwitch metric
TTM (last 4 quarters)
$1.34B
YoY change
+23.0%
5Y CAGR
+25.3%
Peak year (2025)
$1.16B
Cumulative EBITDA
$3.94B
EBITDA history chart for DexCom (DXCM) from 2000 to 2025
EBITDA history table for DexCom (DXCM) from 2000 to 2025
| Fiscal year | Period ended | Reported | EBITDA | YoY |
|---|---|---|---|---|
| 2025 | $1.16B | +23.0% | ||
| 2024 | $945.70M | +3.2% | ||
| 2023 | $916.70M | +62.2% | ||
| 2022 | $565.30M | +49.7% | ||
| 2021 | $377.50M | +0.2% | ||
| 2020 | $376.80M | +76.7% | ||
| 2019 | $213.20M | -385.4% | ||
| 2018 | -$74.70M | +279.2% | ||
| 2017 | -$19.70M | -60.0% | ||
| 2016 | -$49.20M | +6.3% | ||
| 2015 | -$46.30M | +253.4% | ||
| 2014 | -$13.10M | -40.2% | ||
| 2013 | -$21.90M | -55.3% | ||
| 2012 | -$49.00M | +19.6% | ||
| 2011 | -$40.98M | -19.9% | ||
| 2010 | -$51.19M | +18.7% | ||
| 2009 | -$43.11M | -13.4% | ||
| 2008 | -$49.79M | +14.9% | ||
| 2007 | -$43.34M | -7.0% | ||
| 2006 | -$46.62M | +57.0% | ||
| 2005 | -$29.70M | +126.2% | ||
| 2004 | -$13.13M | +33.6% | ||
| 2003 | -$9.83M | +55.8% | ||
| 2002 | -$6.31M | -6.1% | ||
| 2001 | -$6.72M | +67.5% | ||
| 2000 | -$4.01M | — |
EBITDA values are taken from DexCom's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
The 2025 reading of DexCom (DXCM) EBITDA is $1.16B – grew 23.0% year-over-year.
DexCom EBITDA has grown for 7 consecutive years, with a +25.3% compound annual growth rate over 2020–2025 (5 years).
The dataset's maximum EBITDA sits at $1.16B (2025); the minimum reading of -$74.70M dates to 2018.
Within Healthcare, DexCom (DXCM) ranks 9th among 8 peers we track. The peer median for EBITDA is $24.21B.
DexCom EBITDA by Year
DexCom EBITDA 2025: $1.16B
DexCom EBITDA in 2025 was $1.16B, grew 23.0% from 2024. This figure represents the highest annual value in the available history.
DexCom EBITDA 2024: $945.70M
DexCom EBITDA in 2024 was $945.70M, edged up 3.2% from 2023.
DexCom EBITDA 2023: $916.70M
DexCom EBITDA in 2023 was $916.70M, surged 62.2% from 2022.
DexCom EBITDA 2022: $565.30M
DexCom EBITDA in 2022 was $565.30M, surged 49.7% from 2021.
DexCom EBITDA 2021: $377.50M
DexCom EBITDA in 2021 was $377.50M.
See more financial history for DexCom (DXCM).
Sector peers — EBITDA
Companies in the same sector as DexCom, ranked by their latest EBITDA.
| Company | EBITDA | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $156.73B | Healthcare |
| Johnson & Johnson (JNJ) | $41.05B | Healthcare |
| Eli Lilly and Company (LLY) | $27.94B | Healthcare |
| Merck & Co., Inc. (MRK) | $25.36B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $23.06B | Healthcare |
| AstraZeneca PLC (AZN) | $19.83B | Healthcare |
| AbbVie Inc. (ABBV) | $17.63B | Healthcare |
| Amgen Inc. (AMGN) | $15.84B | Healthcare |
Frequently asked questions
What is DexCom's EBITDA?
- Latest reported EBITDA for DexCom (DXCM) is $1.34B (period ending December 31, 2025).
How has DexCom EBITDA changed year-over-year?
- DexCom (DXCM) EBITDA changed +23.0% year-over-year on the latest annual filing.
What is the long-term growth rate of DexCom EBITDA?
- DexCom (DXCM) EBITDA compound annual growth rate is +25.3% over the most recent 5 years available.
When did DexCom EBITDA hit its highest annual value?
- DexCom EBITDA reached its highest annual value of $1.16B in 2025.
What was DexCom EBITDA in 2024?
- DexCom (DXCM) EBITDA in 2024 was $945.70M.
What was DexCom EBITDA in 2025?
- DexCom (DXCM) EBITDA in 2025 was $1.16B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
DXCM Overview
Company profile, financial tools, and key metrics
DXCM Revenue Counter
Earns $147.83 every second. See per minute, hour, and day.
DXCM Earnings Counter
Earns $26.52 per second net profit. See per minute, hour, and day.
DXCM Economic Scale
Exceeds Suriname's GDP. Compare with world economies.
DXCM What If Invested
What if you had invested $1,000? See historical returns from any date.
DXCM How It Makes Money
Discover visual breakdown of $4.66B in revenue — where it comes from and where it goes.
DXCM Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
DXCM Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
DXCM Daily Price Character
Explosive · 49.4% historical win rate (green days). Streaks & record days.
DXCM Buybacks
1.95% TTM buyback yield. Shareholder yield & SBC comparison.
DXCM Stock Split History
1 split on record. Dates, ratios, and cumulative multiple.